1. Volume 5, Issue 3, Pages 291-299 (March 2002)
Induction of a Systemic Immune Response by a Polyvalent Melanoma-Associated Antigen DNA Vaccine for Prevention and Treatment of Malignant Melanoma 
Maki Tanaka, Yasufumi Kaneda, Shigeyuki Fujii, Tomoki Yamano, Kahoko Hashimoto, Sharon K.S. Huang, Dave S.B. Hoon 
Molecular Therapy 
Volume 5, Issue 3, Pages (March 2002)
DOI: /mthe
Copyright © 2002 American Society for Gene Therapy Terms and Conditions

2. Fig. 1
Western blot analysis of human MAA proteins. In vitro transfected NIH3T3 cells with plasmid containing human TRP-2 (lane C) or human gp100 (lane D) were assessed. Controls consisted of NIH3T3 cells not transfected (lane A) and NIH3T3 cells transfected with control plasmid (lane B).
Molecular Therapy 2002 5, DOI: ( /mthe )
Copyright © 2002 American Society for Gene Therapy Terms and Conditions

3. Fig. 2
Assessment of DTH response to gp100 and TRP-2 after i.m. DNA vaccine immunization. Mice were challenged with gp100 protein (A) or TRP-2 protein (B). After 24 hours (open bar) and 48 hours (filled bar), the thickness of the footpad swelling was measured. Bars represent mean units ± SD (five mice per group). *Comparison of vaccine-treated versus respective control at 24 hours (p < 0.01). **Comparison of vaccine treated versus respective control at 48 hours (P < 0.01).
Molecular Therapy 2002 5, DOI: ( /mthe )
Copyright © 2002 American Society for Gene Therapy Terms and Conditions

4. Fig. 3
Assessment of DTH response to gp100 and TRP-2 after i.n. DNA vaccine immunization. Mice were challenged with gp100 protein (A) or TRP-2 protein (B). After 24 hours (open bar) and 48 hours (filled bar), the thickness of the footpad swelling was measured. Bars represent mean units ± SD (five mice per group). *Comparison of vaccine-treated versus respective control at 24 hours (P < 0.01). **Comparison of vaccine-treated versus respective control at 48 hours (**p < 0.01).
Molecular Therapy 2002 5, DOI: ( /mthe )
Copyright © 2002 American Society for Gene Therapy Terms and Conditions

5. Fig. 4
Expression of MAA protein expressed in in wVo-transfected muscle. Transfected tissue samples were dissected 5 days after immunization. Paraffin-embedded tissue sections were immunostained with anti-gp100 antibody and counterstained with hematoxylin: (A) Control plasmid treatment (× 200). (B) gp100 vaccine treatment (× 200). Paraffin-embedded tissue sections were immunostained with anti-TRP-2 antibody and counterstained with hematoxylin. (C) TRP-2 vaccine treatment (× 400).
Molecular Therapy 2002 5, DOI: ( /mthe )
Copyright © 2002 American Society for Gene Therapy Terms and Conditions

6. Fig. 5
Protection against melanoma progression by gp100 and TRP-2 DNA vaccine. Animals were immunized (three times) i.m. and subsequently challenged with B16 melanoma cells. Control group with plasmid alone (n = 7 mice). Vaccine treatment groups (n = 5 mice). Each point represents mean of tumor size with SEM bars of animals of each group. Curves of two groups were significantly different (P < 0.01).
Molecular Therapy 2002 5, DOI: ( /mthe )
Copyright © 2002 American Society for Gene Therapy Terms and Conditions

7. Fig. 6
Survival analysis of mice immunized with gp100 and TRP-2 DNA vaccine in a prophylactic treatment model. Control plasmid group (n = 7 mice), and vaccine treatment group (n = 5 mice). Animals were immunized i.m. and subsequently challenged with B16 melanoma cells. Comparison of survival curves of two groups were significantly different (P < 0.01).
Molecular Therapy 2002 5, DOI: ( /mthe )
Copyright © 2002 American Society for Gene Therapy Terms and Conditions

8. Fig. 7
Protection against melanoma progression by TRP-2 DNA vaccine alone. Animals were immunized with vaccine i.m. and subsequently challenged with B16 melanoma cells; control plasmid treated group (n = 5), and TRP-2 vaccine group (n = 5). Each point represents mean with SEM bars. Comparison of curves of two groups were not significantly different.
Molecular Therapy 2002 5, DOI: ( /mthe )
Copyright © 2002 American Society for Gene Therapy Terms and Conditions

9. Fig. 8
Effect of DNA immunization plus CpG oligonucleotides. Animals (five per group) were immunized (three times) i.m. with vaccine and challenged with B16 melanoma cells s.c. Tumor growth was assessed for three groups: no treatment; DNA vaccine plus CpG oligonucleotide; and DNA vaccine plus control oligonucleotide. Each point represents mean with SEM bars. Nontreated group was significantly different (P < 0.01) from CpG oligonucleotide plus DNA vaccine or control oligonucleotide plus DNA vaccine. There was no significant difference between DNA vaccine plus CpG oligonucleotide and control oligonucleotide.
Molecular Therapy 2002 5, DOI: ( /mthe )
Copyright © 2002 American Society for Gene Therapy Terms and Conditions

10. Fig. 9
Therapeutic effect of gp100 and TRP-2 DNA vaccine against B16 melanoma. Animals were given B16 melanoma cells and then subsequently immunized i.m. (three times). Control plasmid group (n = 9) and vaccine group (n = 9) are shown. Each point represents mean with SEM bars. Curves of two groups were significantly different (P < 0.01).
Molecular Therapy 2002 5, DOI: ( /mthe )
Copyright © 2002 American Society for Gene Therapy Terms and Conditions

11. Fig. 10
Survival analysis of mice treated with gp100 and TRP-2 DNA vaccine in a therapeutic model system. Control plasmid group (n = 9 mice) and vaccine group (n = 9 mice) are shown. Curves of the two groups were significantly different (P < 0.01).
Molecular Therapy 2002 5, DOI: ( /mthe )
Copyright © 2002 American Society for Gene Therapy Terms and Conditions